Substrate
financeSourced

Triller Group Receives Nasdaq Delisting Notice

Triller Group Inc. filed an 8-K disclosing that Nasdaq has notified the company it no longer satisfies a listing rule. The notice starts a regulatory clock that requires the company to regain compliance or face removal from the exchange.

SEC EDGAR — Triller Group Inc.
1 source·Jun 1, 8:00 PM·1m read
Triller Group Receives Nasdaq Delisting Noticemusicbusinessworldwide.com
Audio version
Tap play to generate a narrated version.

Triller Group Inc. told the Securities and Exchange Commission on June 2, 2026 that it received a notice of delisting from Nasdaq, according to an 8-K filed that day.

The filing, submitted under Item 3.01, states that Nasdaq determined Triller Group no longer meets a listing requirement. Item 9.01 of the same document includes exhibits related to the notice. The company is identified by CIK 0001769624.

Triller Group is a publicly reporting company whose shares have traded on Nasdaq. The delisting notice changes its status from presumed compliance to a company operating under a formal deficiency determination. The exact listing rule violated and any cure period granted by Nasdaq are stated in the notice itself, which the company attached as an exhibit.

Operationally, Triller Group must now respond to the exchange according to Nasdaq procedures. If the company submits a plan to regain compliance and Nasdaq accepts it, a compliance extension may be granted. Absent such relief or successful cure, Nasdaq will issue a final delisting determination, after which the company's shares would no longer trade on the exchange.

The company will be required to file any additional updates on material developments, including any appeal or hearing request, via subsequent Form 8-K filings.

Downstream, the delisting process triggers deadlines under exchange rules and SEC reporting obligations. A final delisting decision would require the company to evaluate alternative trading venues such as OTC markets, which carry different liquidity, reporting, and investor-base characteristics.

Creditors, counterparties, or contractual agreements that reference Nasdaq listing status as a covenant may also need to be notified or renegotiated once the status changes.

This marks the first public disclosure by Triller Group of a Nasdaq delisting notice in the current reporting cycle. The filing follows standard SEC requirements for Item 3.01 events, which mandate prompt disclosure when an issuer receives formal notice that it no longer satisfies exchange listing standards.

Coverage spread

Substrate’s article above is written from the primary record. Below: how mainstream outlets reported the same event.

No mainstream coverage of this story has surfaced yet.

Transparency

Confidence90%

Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.

Related Stories

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effectthehindu.com
finance42 min ago

U.S. Strikes Botswana-Flagged Tanker in International Waters; Iran Blockade in Effect

A U.S. aircraft fired an AGM-114 Hellfire missile into the engine room of the M/T Lexie on Tuesday, disabling the unladen vessel as it headed toward Kharg Island. The strike followed repeated ignored warnings over 24 hours.

FI
FI
OS
BBC News
4 sources
Fed Chairman Names Two Outside Advisers During Transitionprnewswire.com
finance42 min ago

Fed Chairman Names Two Outside Advisers During Transition

Federal Reserve Chairman Kevin Warsh appointed two interim advisers shortly after taking the post. One previously contributed to a conservative plan calling for major changes at the central bank.

FI
Wall Street Journal
2 sources
Forte Biosciences Accepts Resignation of Director David Veitchinsidermonkey.com
finance2 hrs agoSourced

Forte Biosciences Accepts Resignation of Director David Veitch

Forte Biosciences disclosed the resignation of independent director David Veitch from its board effective June 1 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure obligations for director changes at the clinical-stage biopharmace…

SEC EDGAR — Forte Biosciences, Inc. (FBRX)
1 source